Choreo LLC Takes $733,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Choreo LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,801 shares of the company’s stock, valued at approximately $733,000.

Other institutional investors have also added to or reduced their stakes in the company. Rise Advisors LLC bought a new position in Medpace during the 1st quarter worth $27,000. Mather Group LLC. acquired a new position in shares of Medpace in the first quarter valued at about $28,000. Fidelis Capital Partners LLC bought a new position in Medpace during the first quarter worth about $31,000. J.Safra Asset Management Corp raised its stake in Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 47 shares in the last quarter. Finally, DT Investment Partners LLC bought a new stake in Medpace in the 2nd quarter valued at about $41,000. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MEDP shares. Robert W. Baird lowered their target price on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Guggenheim lowered their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. Mizuho started coverage on Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $423.00.

Medpace Trading Up 2.0 %

Shares of NASDAQ MEDP opened at $351.67 on Friday. The company has a market cap of $10.90 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 1.74 and a beta of 1.35. Medpace Holdings, Inc. has a 12 month low of $227.21 and a 12 month high of $459.77. The stock has a 50-day moving average price of $384.27 and a two-hundred day moving average price of $393.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. During the same period in the prior year, the company earned $1.93 EPS. The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.